The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Efficacy, Safety, and Tolerability of Pregabalin Treatment for Painful Diabetic Peripheral Neuropathy
Open accessAbstract
OBJECTIVE—To evaluate the efficacy, safety, and tolerability of pregabalin across the effective dosing range, to determine differences in the efficacy of three times daily (TID) versus twice daily (BID) dosage schedules, and to use time-to-event analysis to determine the time to onset of a sustained therapeutic effect using data from seven trials of pregabalin in painful diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS—Data were pooled across seven double-blind, randomized, placebo-controlled trials using pregabalin to treat painful DPN with dosages of 150, 300, and 600 mg/day administered TID or BID. Only one trial included all three of these dosages, and TID dosing was used in four. All studies shared fundamental selection criteria, and treatment durations ranged from 5 to 13 weeks. RESULTS—Pooled analysis showed that pregabalin significantly reduced pain and pain-related sleep interference associated with DPN (150, 300, and 600 mg/day administered TID vs. placebo, all P ≤ 0.007). Only the 600 mg/day dosage showed efficacy when administered BID (P ≤ 0.001). Pain and sleep interference reductions associated with pregabalin appear to be positively correlated with dosage; the greatest effect was observed in patients treated with 600 mg/day. Kaplan-Meier analysis revealed that the median time to onset of a sustained (≥30% at end point) 1-point improvement was 4 days in patients treated with pregabalin at 600 mg/day, 5 days in patients treated with pregabalin at 300 mg/day, 13 days in patients treated with pregabalin at 150 mg/day, and 60 days in patients receiving placebo. The most common treatment-emergent adverse events were dizziness, somnolence, and peripheral edema. CONCLUSIONS—Treatment with pregabalin across its effective dosing range is associated with significant, dose-related improvement in pain in patients with DPN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Boulton, A. J. M., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R., Malik, R. A., Maser, R. E., Sosenko, J. M., & Ziegler, D. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.956 · Cited by 1,859
Self-citationBackonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,533
Pirart, J. (1978) · Diabetes Care · doi:10.2337/diacare.1.3.168 · Cited by 1,290
Sima, A. A. F., Thomas, P. K., Ishii, D., & Vinik, A. (1997) · Diabetologia · doi:10.1007/bf03168192 · Cited by 822
Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial
Dworkin, R. H., Corbin, A. E., Young, J. P., Sharma, U., LaMoreaux, L., Bockbrader, H., Garofalo, E. A., & Poole, R. M. (2003) · Neurology · doi:10.1212/01.wnl.0000055433.55136.55 · Cited by 768
The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes
Davies, M., Brophy, S., Williams, R., & Taylor, A. (2006) · Diabetes Care · doi:10.2337/dc05-2228 · Cited by 746
Rosenstock, J., Tuchman, M., LaMoreaux, L., & Sharma, U. (2004) · Pain · doi:10.1016/j.pain.2004.05.001 · Cited by 725
Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life
Galer, B. S., Gianas, A., & Jensen, M. P. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00112-6 · Cited by 601
Freynhagen, R., Strojek, K., Griesing, T., Whalen, E., & Balkenohl, M. (2005) · Pain · doi:10.1016/j.pain.2005.02.032 · Cited by 572
Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial
Lesser, H., Sharma, U., LaMoreaux, L., & Poole, R. M. (2004) · Neurology · doi:10.1212/01.wnl.0000145767.36287.a1 · Cited by 570
Sabatowski, R., Gálvez, R., Cherry, D. A., Jacquot, F., Vincent, E., Maisonobe, P., & Versavel, M. (2004) · Pain · doi:10.1016/j.pain.2004.01.001 · Cited by 527
Richter, R. W., Portenoy, R., Sharma, U., Lamoreaux, L., Bockbrader, H., & Knapp, L. E. (2005) · The Journal of Pain · doi:10.1016/j.jpain.2004.12.007 · Cited by 473
Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials
Backonja, M., & Glanzman, R. L. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90011-7 · Cited by 425
Ca2+ channel α2δ ligands: novel modulators of neurotransmission
Dooley, D. J., Taylor, C. P., Donevan, S., & Feltner, D. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.12.006 · Cited by 387
van Seventer, R., Feister, H. A., Young, J. P., Stoker, M., Versavel, M., & Rigaudy, L. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x80404 · Cited by 264
Topiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects
Raskin, P., Donofrio, P. D., Rosenthal, N. R., Hewitt, D. J., Jordan, D. M., Xiang, J., & Vinik, A. I. (2004) · Neurology · doi:10.1212/01.wnl.0000137341.89781.14 · Cited by 239
Pirart, J. (1977) · PubMed · Cited by 220
Tölle, T., Freynhagen, R., Versavel, M., Trostmann, U., & Young, J. P. (2008) · European Journal of Pain · doi:10.1016/j.ejpain.2007.05.003 · Cited by 219
GORSON, K. C., SCHOTT, C., HERMAN, R., ROPPER, A. H., & RAND, W. M. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.251 · Cited by 206
The Topiramate Diabetic Neuropathic Pain Study Group*, Thienel, U., Neto, W., Schwabe, S. K., & Vijapurkar, U. (2004) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2004.00338.x · Cited by 187
Vinik, A. I., Tuchman, M., Safirstein, B., Corder, C., Kirby, L., Wilks, K., Quessy, S., Blum, D., Grainger, J., White, J., et al. (2007) · Pain · doi:10.1016/j.pain.2006.09.040 · Cited by 163
Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy
Freeman, R. L., Raskin, P., Hewitt, D., Vorsanger, G., Jordan, D. M., Xiang, J. X., Rosenthal, N. R., & for the CAPSS-237 Study Group (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x162674 · Cited by 116
Self-citationA randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy
Großkopf, J., Mazzola, J., Wan, Y., & Hopwood, M. B. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2005.00559.x · Cited by 94
Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study
Beydoun, A. A., Shaibani, A. I., Hopwood, M. B., & Wan, Y. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00631.x · Cited by 92
Cited by
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Self-citationDiabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
Self-citationEFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Japanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
Metadata
- Authors
- Freeman, R., Durso-DeCruz, E., & Emir, B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-07-01
- Volume
- 31
- Issue
- 7
- Pages
- 1448-1454
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2120306614
- Cited by
- 322
- References
- 25
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.